News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
TipRanks Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
CollPlant Biotechnologies Ltd. (CLGN) announced that its shareholders approved a proposal at an Extraordinary General Meeting (EGM) held on July 29, 2026. The proposal, detailed in a notice dated July 7, 2026, was approved by the required majority. This report is incorporated by reference …
A Loewenbaum-led investor group and related entities have reported a combined beneficial holding of 3,518,237 Ordinary Shares in CollPlant Biotechnologies (CLGN), representing 18.6% of outstanding shares. The Loewenbaum 1992 Trust recently purchased 1,764,706 Ordinary Shares along with Series A and Series B Warrants. These …
This article provides a comprehensive stock analysis of Collplant Biotechnologies Ltd (CLGN) from TradingKey. It highlights the company's healthy fundamentals and significant growth potential, although its valuation is considered fairly valued within the Biotechnology & Medical Research industry. Despite high institutional ownership and analyst …
This article provides a revenue breakdown for CollPlant Biotechnologies Ltd. (NASDAQ: CLGN), highlighting that the United States was the largest contributor to its revenue. The company recorded $2.18 million USD from the U.S. last year, an increase from $484,000 USD the previous year.
CollPlant Biotechnologies Ltd. (CLGN) has completed an exempt private securities offering, raising $10.4 million under Rule 506(b) of Regulation D. The offering included equity, Series A and Series B warrants, and underlying ordinary shares. H.C. Wainwright & Co., LLC served as the placement agent, …
CollPlant Biotechnologies has filed to register for resale up to 31,047,068 ordinary shares by existing investors. These shares include PIPE shares and those issuable upon the exercise of various warrants from a June-July 2026 private placement. While CollPlant will not receive proceeds from the …
CollPlant Biotechnologies Ltd (CLGN) has announced an SEC filing, specifically a Notice of Effectiveness for Form F-3, dated July 16, 2026, at 4:00 P.M. The filing, with CIK 0001631487 and file number 333-297347, was accepted by SEC EDGAR on July 17, 2026. This indicates …
Search by ticker symbol or company name and select a result to open its chart.